# COPD diagnosis and treatment developments

> Developing situation record from CLSTR: https://clstr.news/situations/copd-diagnosis-and-treatment-developments
> Updated: 2026-11-16T22:01:53.000Z. Sources: 28. Developments: 2.

Medical experts are emphasizing the critical need for early diagnosis of chronic obstructive pulmonary disease (COPD) to improve patient outcomes. Research is currently exploring anti-alarmin therapies, such as itepekimab and astegolimab, to manage disease exacerbations driven by pollutants, bacteria, or viruses.

In Spain, health professionals and patient associations are specifically calling for improved detection, noting that approximately 75 percent of cases remain undiagnosed. Local initiatives, such as those in Fuerteventura, have implemented free screening tests and awareness programs to encourage smokers and former smokers to seek medical evaluation.

During World COPD Day observations, the global scale of the issue was highlighted, noting that COPD is the third leading cause of death, claiming over 3 million lives annually. While Spain faces a 75 percent underdiagnosis rate, Italy reports that an estimated 70 percent of cases are diagnosed with significant delays. New data from 2026 indicates that Canada faces a similarly high undiagnosed rate of roughly 80 percent.

Medical professionals warn that symptoms like persistent cough, shortness of breath, and frequent phlegm are often mistakenly attributed to aging. Risk factors include tobacco use, air pollution, biomass smoke, and occupational exposure to chemicals or dust. Experts stress that early diagnosis through spirometry and the use of respiratory physiotherapy are vital to preserving lung function and patient autonomy.

Treatment options are expanding. In Spain, the public health system has approved funding for biological treatments, specifically dupilumab and mepolizumab. These therapies target specific inflammatory mechanisms and are expected to benefit approximately 25,000 patients who experience frequent exacerbations despite standard inhaled therapies. Beyond physical symptoms, experts note that the disease can impact mental health, contributing to anxiety and social isolation.

## Claims

- COPD is the third leading cause of death globally. (reported by 2 sources)
- Approximately 75% of COPD cases in Spain remain undiagnosed. (reported by 2 sources)
- The prevalence of COPD in Spain is 11.8% among the population over 40. (reported by 2 sources)
- In Italy, COPD affects approximately 3.5 million adults. (reported by 2 sources)
- In Canada, about 80% of patients living with COPD are unaware of their diagnosis. (reported by 1 source)
- Dupilumab and mepolizumab were approved for public funding in Spain in July 2026. (reported by 1 source)
- COPD caused 19,136 deaths in Mexico in 2024. (reported by 1 source)
- In Argentina, over 2 million people over age 40 may be affected by COPD. (reported by 1 source)

## Timeline

### 2026-11-16: World COPD Day: Global health experts warn of high undiagnosed rates

On World COPD Day, medical experts warn that millions suffer from undiagnosed chronic obstructive pulmonary disease, urging early detection via spirometry to combat high global mortality rates.

28 sources. https://clstr.news/cluster/health-experts-call-for-improved-copd-detection-in-spain

### 2026-11-05: Medical experts emphasize early COPD diagnosis and anti-alarmin therapies

Medical experts advocate for earlier COPD diagnosis and the development of anti-alarmin therapies to reduce exacerbations and improve long-term patient outcomes.

2 sources. https://clstr.news/cluster/medical-experts-emphasize-early-copd-diagnosis-and-anti-alarmin-therapies

---
Cite as: COPD diagnosis and treatment developments. CLSTR, https://clstr.news/situations/copd-diagnosis-and-treatment-developments
